Atara Biotherapeutics (NASDAQ:ATRA) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
Insider and Institutional Ownership
43.1% of Applied Genetic Technologies shares are held by institutional investors. 10.6% of Atara Biotherapeutics shares are held by insiders. Comparatively, 6.9% of Applied Genetic Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Atara Biotherapeutics and Applied Genetic Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Applied Genetic Technologies||4.06%||2.22%||1.71%|
Risk & Volatility
Atara Biotherapeutics has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Atara Biotherapeutics and Applied Genetic Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Applied Genetic Technologies||0||2||3||0||2.60|
Atara Biotherapeutics presently has a consensus price target of $43.33, suggesting a potential upside of 75.23%. Applied Genetic Technologies has a consensus price target of $9.60, suggesting a potential upside of 164.46%. Given Applied Genetic Technologies’ higher possible upside, analysts clearly believe Applied Genetic Technologies is more favorable than Atara Biotherapeutics.
Valuation and Earnings
This table compares Atara Biotherapeutics and Applied Genetic Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atara Biotherapeutics||N/A||N/A||-$230.70 million||($5.27)||-4.69|
|Applied Genetic Technologies||$24.19 million||2.73||-$21.30 million||($1.18)||-3.08|
Applied Genetic Technologies has higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.
Applied Genetic Technologies beats Atara Biotherapeutics on 10 of the 12 factors compared between the two stocks.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.